Eisai (ESALY) and Biogen (BIIB) announced that the European Medicines Agency has accepted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease with confirmed amyloid pathology, for review following a standard timeline.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
- Ionis confirms FDA to hold advisory committee meeting on tofersen NDA
- Biogen says FDA to convene advisory committee meeting for tofersen
- Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
- Eisai submits marketing authorization application for lecanemab in Japan